The Stock that Jumped 177% in the Evening Shows: The Experiment Was Successful, the Short Failed
7 Articles
7 Articles
A successful trial of a melanoma cancer vaccine led to a huge jump in Moderna's stock, which has been struggling to find its way since the coronavirus • Investors who bet against the stock lost billions, some tried to save their money last night
Moderna and Merck not only delight patients with good results of a cancer vaccine - but also their shareholders. The Moderna share jumped by 176 percent yesterday. Also because this is about more than one vaccine.
A cancer vaccine from Merck and Moderna has shown positive initial results. The vaccine slows the return of aggressive skin cancer. The news sent Moderna's stock soaring on the stock market.
The US plan to double public debt buybacks eases the pressure on bonds and sustains the Dow Jones and the S&P 500, while Nasdaq 100 closes in negative. Modern starring the session with an extraordinary rise after advances in melanoma are known.
Merck's shares also rebounded in the stock market 12% in New York for advances in his research. He liked an experimental vaccine.
Moderna and Merck have successfully completed the final phase of testing mRNA therapy for melanoma. Moderna's shares rose 150 percent before trading opened.
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
